Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric S Daar

Showing results (131-140 of 222) with videos related to

Pageof 23
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 12, 2017
Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR StudyDavid J Moore, Sonia Jain, Michael P Dubé, et al.
The Lancet. HIV|June 22, 2018
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trialEric S Daar, Edwin DeJesus, Peter Ruane, et al.
Lancet (London, England)|September 5, 2017
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialJoel Gallant, Adriano Lazzarin, Anthony Mills, et al.
Contemporary Clinical Trials|March 27, 2025
Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trialMark J Giganti, Kara W Chew, Carlee Moser, et al.
Scientific Reports|March 20, 2026
Association of long COVID with health-related quality-of-life outcomesMalini M Gandhi, Carlee Moser, Judith S Currier, et al.
Annals of Internal Medicine|February 21, 2023
Symptom and Viral Rebound in Untreated SARS-CoV-2 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 21, 2014
Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimensYu Zheng, Michael D Hughes, Shahin Lockman, et al.
The Journal of Infectious Diseases|December 20, 2011
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individualsChristine M Hogan, Victor Degruttola, Xin Sun, et al.
Medrxiv : the Preprint Server for Health Sciences|August 19, 2022
Viral and Symptom Rebound in Untreated COVID-19 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical TrialsCarlee B Moser, Kara W Chew, Mark J Giganti, et al.
Pageof 23

Showing results (131-140 of 222) with videos related to

Sort By:
Pageof 23
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 12, 2017
Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR StudyDavid J Moore, Sonia Jain, Michael P Dubé, et al.
The Lancet. HIV|June 22, 2018
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trialEric S Daar, Edwin DeJesus, Peter Ruane, et al.
Lancet (London, England)|September 5, 2017
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialJoel Gallant, Adriano Lazzarin, Anthony Mills, et al.
Contemporary Clinical Trials|March 27, 2025
Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trialMark J Giganti, Kara W Chew, Carlee Moser, et al.
Scientific Reports|March 20, 2026
Association of long COVID with health-related quality-of-life outcomesMalini M Gandhi, Carlee Moser, Judith S Currier, et al.
Annals of Internal Medicine|February 21, 2023
Symptom and Viral Rebound in Untreated SARS-CoV-2 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 21, 2014
Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimensYu Zheng, Michael D Hughes, Shahin Lockman, et al.
The Journal of Infectious Diseases|December 20, 2011
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individualsChristine M Hogan, Victor Degruttola, Xin Sun, et al.
Medrxiv : the Preprint Server for Health Sciences|August 19, 2022
Viral and Symptom Rebound in Untreated COVID-19 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical TrialsCarlee B Moser, Kara W Chew, Mark J Giganti, et al.
Pageof 23